Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.

This study reports that a novel nanolipogel with moderate rigidity (NLG-2.5) enhances transdermal delivery of fucosterol, displaying superior permeability, targeting hair follicles, and promoting hair growth in androgenetic alopecia model mice by inhibiting inflammation and androgen pathways and promoting angiogenesis.

This study found that isorhamnetin, a compound from the Rampai plant, showed a lower affinity energy in molecular docking tests compared to Minoxidil, indicating potential as an androgen receptor antagonist for alopecia therapy in silico, with favorable pharmacokinetic characteristics in ADME-Tox predictions.

This study found that loliolide enhanced hair growth-related functions in 3D dermal papilla spheroids by activating AKT/β-catenin signaling pathways, with increased expression of related growth factors and genes.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This study found that a transdermal drug delivery system using nanostructured lipid carriers and polymeric microneedles for β-sitosterol significantly enhanced hair growth in testosterone-induced alopecia rats, suggesting potential for treating androgenic alopecia.

This study developed an efficient LC-MS bioanalytical method to simultaneously quantify minoxidil sulphate and latanoprost in skin layers, supporting the formulation of topical treatments for androgenic alopecia.

This study found that nanostructured lipid carriers significantly improved the targeted delivery of latanoprost and minoxidil to pilosebaceous units in porcine skin, with latanoprost showing notably higher accumulation.

This review discusses the role of latanoprost in hair growth but reports no clinical results; the authors suggest further research to determine its efficacy and optimal treatment regimen.

A woman got a scalp condition from using latanoprost, but it improved after stopping the drug and starting other treatments.

This study investigated a novel treatment for androgenetic alopecia, combining nanotechnology with a substance called β-sitosterol and laser therapy, and found that this combination showed promise in promoting hair growth without causing irritation or cytotoxicity.

This study identified optimal parameters for extracting oil from Urtica dioica roots to maximize phytosterol content, using corn oil and a 1:5 raw material-extract ratio over a 6-hour maceration period.

This study found that combining a potent steroid with a vitamin D analogue may offer more convenient treatment for localized alopecia areata than using a superpotent steroid alone, with comparable efficacy but fewer side effects.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This review discusses the potential of using sustained release systems to increase the effectiveness and reduce side effects of 17-alpha-estradiol in alopecia treatment and reports no clinical results.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This study found that treatments with 5% minoxidil, with or without latanoprost, were effective in controlling hair loss and increasing hair strand count in patients with telogen effluvium or androgenic alopecia.

This study developed a nanostructured lipid carrier for 17-α-estradiol that showed stable physicochemical properties and improved targeting to hair follicles in alopecia treatment.

This study suggests that a nanostructured lipid carrier formulation delivering minoxidil and latanoprost may enhance effectiveness and tolerability in treating alopecia by targeting hair follicles.

In this study, topical latanoprost acid applied daily for 6 months increased hair count and improved trichoscopic markers among women with hair loss, suggesting its potential for treating female androgenetic alopecia, particularly at a 0.05% concentration.

This article discusses the potential of latanoprost for treating alopecia areata, but notes that well-controlled studies are still needed to confirm its effectiveness.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

In this study, the addition of topical latanoprost to betamethasone treatment improved the therapeutic efficacy for patients with patchy alopecia areata, showing more significant hair regrowth compared to minoxidil alone and enhanced outcomes without adverse effects.

This study found that there was no significant difference in hair regrowth between clobetasol and bimatoprost for scalp alopecia areata over 12 weeks, but bimatoprost had fewer side effects and prompted earlier, more pigmented hair regrowth.

This article reviews the historical discovery and validation of isocholesterol, confirming its identity as a distinct sterol but reports no new research findings.